nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—FGR—lung cancer	0.12	0.371	CbGaD
Nilotinib—BRAF—lung cancer	0.0631	0.195	CbGaD
Nilotinib—KIT—lung cancer	0.0506	0.157	CbGaD
Nilotinib—UGT1A1—lung cancer	0.0499	0.154	CbGaD
Nilotinib—ABCG2—lung cancer	0.028	0.0867	CbGaD
Nilotinib—TIE1—Crizotinib—lung cancer	0.0272	0.0634	CbGbCtD
Nilotinib—EPHA6—Gefitinib—lung cancer	0.0226	0.0525	CbGbCtD
Nilotinib—EPHA4—Crizotinib—lung cancer	0.0216	0.0503	CbGbCtD
Nilotinib—MAP4K1—Crizotinib—lung cancer	0.0216	0.0503	CbGbCtD
Nilotinib—EPHB4—Crizotinib—lung cancer	0.0216	0.0503	CbGbCtD
Nilotinib—EPHA3—Crizotinib—lung cancer	0.0216	0.0503	CbGbCtD
Nilotinib—MAP2K5—Gefitinib—lung cancer	0.0185	0.0429	CbGbCtD
Nilotinib—EPHA8—Crizotinib—lung cancer	0.0181	0.0421	CbGbCtD
Nilotinib—EPHA2—Crizotinib—lung cancer	0.0181	0.0421	CbGbCtD
Nilotinib—TEK—Crizotinib—lung cancer	0.0181	0.0421	CbGbCtD
Nilotinib—FGR—Crizotinib—lung cancer	0.0156	0.0364	CbGbCtD
Nilotinib—LYN—Crizotinib—lung cancer	0.0138	0.0322	CbGbCtD
Nilotinib—BLK—Crizotinib—lung cancer	0.0138	0.0322	CbGbCtD
Nilotinib—EPHB6—Crizotinib—lung cancer	0.0138	0.0322	CbGbCtD
Nilotinib—EPHA6—Crizotinib—lung cancer	0.0138	0.0322	CbGbCtD
Nilotinib—EPHA6—Erlotinib—lung cancer	0.0133	0.031	CbGbCtD
Nilotinib—CSF1R—Crizotinib—lung cancer	0.0124	0.0289	CbGbCtD
Nilotinib—ABL2—Crizotinib—lung cancer	0.0124	0.0289	CbGbCtD
Nilotinib—ABL2—Erlotinib—lung cancer	0.012	0.0279	CbGbCtD
Nilotinib—ABCB1—lung cancer	0.0117	0.0361	CbGaD
Nilotinib—LCK—Crizotinib—lung cancer	0.0113	0.0263	CbGbCtD
Nilotinib—MAP2K5—Erlotinib—lung cancer	0.0109	0.0254	CbGbCtD
Nilotinib—ABL1—Crizotinib—lung cancer	0.00898	0.0209	CbGbCtD
Nilotinib—ABL1—Erlotinib—lung cancer	0.00867	0.0202	CbGbCtD
Nilotinib—ABCG2—Topotecan—lung cancer	0.00366	0.00852	CbGbCtD
Nilotinib—UGT1A1—Erlotinib—lung cancer	0.0036	0.00837	CbGbCtD
Nilotinib—ABCG2—Gefitinib—lung cancer	0.00335	0.00779	CbGbCtD
Nilotinib—UGT1A1—Irinotecan—lung cancer	0.00325	0.00756	CbGbCtD
Nilotinib—ABCG2—Teniposide—lung cancer	0.00325	0.00755	CbGbCtD
Nilotinib—UGT1A1—Etoposide—lung cancer	0.0026	0.00606	CbGbCtD
Nilotinib—CA3—pericardium—lung cancer	0.00205	0.0458	CbGeAlD
Nilotinib—EPHA2—pulmonary artery—lung cancer	0.00201	0.045	CbGeAlD
Nilotinib—ABCG2—Erlotinib—lung cancer	0.00198	0.00461	CbGbCtD
Nilotinib—ABCG2—Paclitaxel—lung cancer	0.00181	0.00422	CbGbCtD
Nilotinib—ABCG2—Irinotecan—lung cancer	0.00179	0.00416	CbGbCtD
Nilotinib—ABCG2—Cisplatin—lung cancer	0.00146	0.00339	CbGbCtD
Nilotinib—ABCG2—Etoposide—lung cancer	0.00143	0.00333	CbGbCtD
Nilotinib—ABCB1—Topotecan—lung cancer	0.00132	0.00307	CbGbCtD
Nilotinib—ABCG2—Docetaxel—lung cancer	0.00131	0.00305	CbGbCtD
Nilotinib—CYP2B6—Irinotecan—lung cancer	0.00126	0.00293	CbGbCtD
Nilotinib—CYP2C9—Gefitinib—lung cancer	0.00124	0.00289	CbGbCtD
Nilotinib—ABCB1—Gefitinib—lung cancer	0.00121	0.00281	CbGbCtD
Nilotinib—CYP2C9—Teniposide—lung cancer	0.00121	0.00281	CbGbCtD
Nilotinib—EPHB2—Irinotecan—Topotecan—lung cancer	0.00115	0.698	CbGdCrCtD
Nilotinib—CYP2D6—Gefitinib—lung cancer	0.00114	0.00265	CbGbCtD
Nilotinib—CYP2C8—Erlotinib—lung cancer	0.00105	0.00245	CbGbCtD
Nilotinib—CYP2B6—Cisplatin—lung cancer	0.00102	0.00238	CbGbCtD
Nilotinib—ABCG2—Doxorubicin—lung cancer	0.000977	0.00227	CbGbCtD
Nilotinib—CYP2C8—Paclitaxel—lung cancer	0.000965	0.00225	CbGbCtD
Nilotinib—MAPK11—mammary gland—lung cancer	0.000958	0.0215	CbGeAlD
Nilotinib—CDC42BPB—mammary gland—lung cancer	0.00095	0.0213	CbGeAlD
Nilotinib—ABCG2—Methotrexate—lung cancer	0.000946	0.0022	CbGbCtD
Nilotinib—ABCB1—Vinorelbine—lung cancer	0.00093	0.00216	CbGbCtD
Nilotinib—CYP2D6—Vinorelbine—lung cancer	0.000876	0.00204	CbGbCtD
Nilotinib—CYP3A4—Topotecan—lung cancer	0.000791	0.00184	CbGbCtD
Nilotinib—CYP2C8—Etoposide—lung cancer	0.000763	0.00177	CbGbCtD
Nilotinib—ABCB1—Crizotinib—lung cancer	0.00074	0.00172	CbGbCtD
Nilotinib—CYP3A4—Gefitinib—lung cancer	0.000723	0.00168	CbGbCtD
Nilotinib—ABCB1—Gemcitabine—lung cancer	0.000723	0.00168	CbGbCtD
Nilotinib—Ponatinib—FGFR1—lung cancer	0.000716	0.253	CrCbGaD
Nilotinib—ABCB1—Erlotinib—lung cancer	0.000714	0.00166	CbGbCtD
Nilotinib—EPHB3—mammary gland—lung cancer	0.000709	0.0159	CbGeAlD
Nilotinib—CYP3A4—Teniposide—lung cancer	0.000701	0.00163	CbGbCtD
Nilotinib—CYP2B6—Doxorubicin—lung cancer	0.000687	0.0016	CbGbCtD
Nilotinib—CYP2C9—Paclitaxel—lung cancer	0.000673	0.00157	CbGbCtD
Nilotinib—CYP2D6—Erlotinib—lung cancer	0.000672	0.00156	CbGbCtD
Nilotinib—ABCB1—Paclitaxel—lung cancer	0.000653	0.00152	CbGbCtD
Nilotinib—ABCB1—Irinotecan—lung cancer	0.000645	0.0015	CbGbCtD
Nilotinib—CDC42BPB—respiratory system—lung cancer	0.000633	0.0142	CbGeAlD
Nilotinib—ABCB1—Vinblastine—lung cancer	0.000573	0.00133	CbGbCtD
Nilotinib—MAPK8—respiratory system—lung cancer	0.000573	0.0128	CbGeAlD
Nilotinib—CYP3A4—Vinorelbine—lung cancer	0.000557	0.0013	CbGbCtD
Nilotinib—CYP2C9—Cisplatin—lung cancer	0.000541	0.00126	CbGbCtD
Nilotinib—CYP2D6—Vinblastine—lung cancer	0.00054	0.00126	CbGbCtD
Nilotinib—ABCB1—Cisplatin—lung cancer	0.000525	0.00122	CbGbCtD
Nilotinib—CDC42BPB—bronchus—lung cancer	0.000521	0.0117	CbGeAlD
Nilotinib—ABCB1—Etoposide—lung cancer	0.000516	0.0012	CbGbCtD
Nilotinib—EPHA2—mammary gland—lung cancer	0.000508	0.0114	CbGeAlD
Nilotinib—TIE1—respiratory system—lung cancer	0.000497	0.0111	CbGeAlD
Nilotinib—TEK—mammary gland—lung cancer	0.000495	0.0111	CbGeAlD
Nilotinib—MAPK8—epithelium—lung cancer	0.000479	0.0107	CbGeAlD
Nilotinib—ABCB1—Docetaxel—lung cancer	0.000472	0.0011	CbGbCtD
Nilotinib—MAPK8—bronchus—lung cancer	0.000471	0.0106	CbGeAlD
Nilotinib—CDC42BPB—trachea—lung cancer	0.000468	0.0105	CbGeAlD
Nilotinib—Ponatinib—SRC—lung cancer	0.000457	0.161	CrCbGaD
Nilotinib—PDGFRA—mammary gland—lung cancer	0.000449	0.01	CbGeAlD
Nilotinib—CYP3A4—Crizotinib—lung cancer	0.000443	0.00103	CbGbCtD
Nilotinib—CDC42BPB—cardiac atrium—lung cancer	0.00044	0.00984	CbGeAlD
Nilotinib—Ponatinib—KDR—lung cancer	0.000429	0.152	CrCbGaD
Nilotinib—MAP4K1—bronchus—lung cancer	0.000428	0.00959	CbGeAlD
Nilotinib—CYP3A4—Erlotinib—lung cancer	0.000428	0.000995	CbGbCtD
Nilotinib—TIE1—epithelium—lung cancer	0.000415	0.00929	CbGeAlD
Nilotinib—Ponatinib—KIT—lung cancer	0.000405	0.143	CrCbGaD
Nilotinib—CSF1R—mammary gland—lung cancer	0.000395	0.00884	CbGeAlD
Nilotinib—CYP3A4—Paclitaxel—lung cancer	0.000391	0.000911	CbGbCtD
Nilotinib—CA3—respiratory system—lung cancer	0.00039	0.00872	CbGeAlD
Nilotinib—EPHB3—bronchus—lung cancer	0.000389	0.0087	CbGeAlD
Nilotinib—CYP3A4—Irinotecan—lung cancer	0.000386	0.000899	CbGbCtD
Nilotinib—MAPK14—respiratory system—lung cancer	0.000364	0.00814	CbGeAlD
Nilotinib—FGR—respiratory system—lung cancer	0.000362	0.00811	CbGeAlD
Nilotinib—KIT—mammary gland—lung cancer	0.000359	0.00803	CbGeAlD
Nilotinib—HCK—bronchus—lung cancer	0.000357	0.008	CbGeAlD
Nilotinib—ABCB1—Doxorubicin—lung cancer	0.000352	0.000819	CbGbCtD
Nilotinib—PDGFRB—mammary gland—lung cancer	0.00035	0.00784	CbGeAlD
Nilotinib—EPHB3—trachea—lung cancer	0.000349	0.00782	CbGeAlD
Nilotinib—EPHB4—respiratory system—lung cancer	0.000345	0.00772	CbGeAlD
Nilotinib—TIE1—cardiac atrium—lung cancer	0.000345	0.00772	CbGeAlD
Nilotinib—CYP3A4—Vinblastine—lung cancer	0.000343	0.000799	CbGbCtD
Nilotinib—ABCB1—Methotrexate—lung cancer	0.000341	0.000794	CbGbCtD
Nilotinib—EPHA2—respiratory system—lung cancer	0.000338	0.00757	CbGeAlD
Nilotinib—CDC42BPB—lung—lung cancer	0.000336	0.00753	CbGeAlD
Nilotinib—MAPK8—bone marrow—lung cancer	0.000336	0.00752	CbGeAlD
Nilotinib—CYP2D6—Doxorubicin—lung cancer	0.000332	0.000772	CbGbCtD
Nilotinib—TEK—respiratory system—lung cancer	0.00033	0.00739	CbGeAlD
Nilotinib—EPHA4—bronchus—lung cancer	0.000325	0.00727	CbGeAlD
Nilotinib—HCK—trachea—lung cancer	0.000321	0.00718	CbGeAlD
Nilotinib—EPHA3—lung—lung cancer	0.000319	0.00714	CbGeAlD
Nilotinib—CA7—trachea—lung cancer	0.000314	0.00703	CbGeAlD
Nilotinib—ABL1—mammary gland—lung cancer	0.000312	0.00699	CbGeAlD
Nilotinib—CYP3A4—Etoposide—lung cancer	0.000309	0.00072	CbGbCtD
Nilotinib—MAP4K1—bone marrow—lung cancer	0.000305	0.00683	CbGeAlD
Nilotinib—MAPK8—lung—lung cancer	0.000304	0.00681	CbGeAlD
Nilotinib—MAPK14—epithelium—lung cancer	0.000304	0.00681	CbGeAlD
Nilotinib—ABL1—Topotecan—Irinotecan—lung cancer	0.000301	0.183	CbGdCrCtD
Nilotinib—MAPK14—bronchus—lung cancer	0.000299	0.0067	CbGeAlD
Nilotinib—PDGFRA—respiratory system—lung cancer	0.000299	0.00669	CbGeAlD
Nilotinib—LCK—bronchus—lung cancer	0.000298	0.00668	CbGeAlD
Nilotinib—EPHA4—trachea—lung cancer	0.000292	0.00653	CbGeAlD
Nilotinib—EPHB4—epithelium—lung cancer	0.000288	0.00645	CbGeAlD
Nilotinib—EPHB4—bronchus—lung cancer	0.000284	0.00635	CbGeAlD
Nilotinib—CYP3A4—Docetaxel—lung cancer	0.000283	0.000659	CbGbCtD
Nilotinib—EPHA2—epithelium—lung cancer	0.000283	0.00633	CbGeAlD
Nilotinib—BRAF—bone marrow—lung cancer	0.000279	0.00625	CbGeAlD
Nilotinib—EPHA2—bronchus—lung cancer	0.000278	0.00623	CbGeAlD
Nilotinib—MAP4K1—lung—lung cancer	0.000276	0.00619	CbGeAlD
Nilotinib—CA12—respiratory system—lung cancer	0.000276	0.00618	CbGeAlD
Nilotinib—TEK—epithelium—lung cancer	0.000276	0.00617	CbGeAlD
Nilotinib—EPHA4—cardiac atrium—lung cancer	0.000274	0.00613	CbGeAlD
Nilotinib—TEK—bronchus—lung cancer	0.000272	0.00608	CbGeAlD
Nilotinib—CA3—cardiac atrium—lung cancer	0.00027	0.00606	CbGeAlD
Nilotinib—LCK—trachea—lung cancer	0.000268	0.00599	CbGeAlD
Nilotinib—TIE1—lung—lung cancer	0.000264	0.0059	CbGeAlD
Nilotinib—CSF1R—respiratory system—lung cancer	0.000263	0.00589	CbGeAlD
Nilotinib—BLK—lymph node—lung cancer	0.000263	0.00589	CbGeAlD
Nilotinib—EPHB6—bronchus—lung cancer	0.00026	0.00581	CbGeAlD
Nilotinib—EPHB4—trachea—lung cancer	0.000255	0.00571	CbGeAlD
Nilotinib—HCK—bone marrow—lung cancer	0.000254	0.0057	CbGeAlD
Nilotinib—BRAF—lung—lung cancer	0.000253	0.00566	CbGeAlD
Nilotinib—EPHB3—lung—lung cancer	0.000251	0.00562	CbGeAlD
Nilotinib—EPHA2—trachea—lung cancer	0.00025	0.0056	CbGeAlD
Nilotinib—Imatinib—KIT—lung cancer	0.000249	0.0881	CrCbGaD
Nilotinib—CA14—cardiac atrium—lung cancer	0.000246	0.0055	CbGeAlD
Nilotinib—EPHB4—cardiac atrium—lung cancer	0.000239	0.00536	CbGeAlD
Nilotinib—KIT—respiratory system—lung cancer	0.000239	0.00535	CbGeAlD
Nilotinib—EPHA2—cardiac atrium—lung cancer	0.000235	0.00526	CbGeAlD
Nilotinib—PDGFRB—respiratory system—lung cancer	0.000233	0.00523	CbGeAlD
Nilotinib—EPHB6—trachea—lung cancer	0.000233	0.00522	CbGeAlD
Nilotinib—MAPK11—lymph node—lung cancer	0.000232	0.00519	CbGeAlD
Nilotinib—HCK—lung—lung cancer	0.00023	0.00516	CbGeAlD
Nilotinib—CDC42BPB—lymph node—lung cancer	0.00023	0.00515	CbGeAlD
Nilotinib—TEK—cardiac atrium—lung cancer	0.000229	0.00513	CbGeAlD
Nilotinib—ABL2—lung—lung cancer	0.000229	0.00513	CbGeAlD
Nilotinib—CA3—bone marrow—lung cancer	0.000228	0.00511	CbGeAlD
Nilotinib—Ponatinib—ABCG2—lung cancer	0.000224	0.0792	CrCbGaD
Nilotinib—MAP2K5—bronchus—lung cancer	0.000222	0.00497	CbGeAlD
Nilotinib—PDGFRA—trachea—lung cancer	0.000221	0.00495	CbGeAlD
Nilotinib—EPHB6—cardiac atrium—lung cancer	0.000219	0.0049	CbGeAlD
Nilotinib—CA1—respiratory system—lung cancer	0.000219	0.00489	CbGeAlD
Nilotinib—EPHA3—lymph node—lung cancer	0.000218	0.00488	CbGeAlD
Nilotinib—CSF1R—bronchus—lung cancer	0.000217	0.00485	CbGeAlD
Nilotinib—MAPK14—bone marrow—lung cancer	0.000213	0.00477	CbGeAlD
Nilotinib—FGR—bone marrow—lung cancer	0.000212	0.00475	CbGeAlD
Nilotinib—LCK—bone marrow—lung cancer	0.000212	0.00475	CbGeAlD
Nilotinib—CYP3A4—Doxorubicin—lung cancer	0.000211	0.000491	CbGbCtD
Nilotinib—EPHA4—lung—lung cancer	0.000209	0.00469	CbGeAlD
Nilotinib—ABL1—respiratory system—lung cancer	0.000208	0.00466	CbGeAlD
Nilotinib—MAPK8—lymph node—lung cancer	0.000208	0.00466	CbGeAlD
Nilotinib—CA3—lung—lung cancer	0.000207	0.00463	CbGeAlD
Nilotinib—CA12—trachea—lung cancer	0.000204	0.00457	CbGeAlD
Nilotinib—CYP2C8—mammary gland—lung cancer	0.000202	0.00453	CbGeAlD
Nilotinib—EPHB4—bone marrow—lung cancer	0.000202	0.00452	CbGeAlD
Nilotinib—KIT—epithelium—lung cancer	0.0002	0.00447	CbGeAlD
Nilotinib—MAP2K5—trachea—lung cancer	0.000199	0.00446	CbGeAlD
Nilotinib—KIT—bronchus—lung cancer	0.000197	0.0044	CbGeAlD
Nilotinib—PDGFRB—epithelium—lung cancer	0.000195	0.00437	CbGeAlD
Nilotinib—CSF1R—trachea—lung cancer	0.000194	0.00436	CbGeAlD
Nilotinib—MAPK14—lung—lung cancer	0.000193	0.00432	CbGeAlD
Nilotinib—LCK—lung—lung cancer	0.000192	0.00431	CbGeAlD
Nilotinib—FGR—lung—lung cancer	0.000192	0.00431	CbGeAlD
Nilotinib—PDGFRB—bronchus—lung cancer	0.000192	0.0043	CbGeAlD
Nilotinib—MAP4K1—lymph node—lung cancer	0.000189	0.00423	CbGeAlD
Nilotinib—MAP2K5—cardiac atrium—lung cancer	0.000187	0.00419	CbGeAlD
Nilotinib—EPHB4—lung—lung cancer	0.000183	0.0041	CbGeAlD
Nilotinib—CSF1R—cardiac atrium—lung cancer	0.000183	0.00409	CbGeAlD
Nilotinib—TIE1—lymph node—lung cancer	0.00018	0.00404	CbGeAlD
Nilotinib—CYP2C9—mammary gland—lung cancer	0.00018	0.00403	CbGeAlD
Nilotinib—EPHA2—lung—lung cancer	0.00018	0.00402	CbGeAlD
Nilotinib—KIT—trachea—lung cancer	0.000177	0.00395	CbGeAlD
Nilotinib—TEK—lung—lung cancer	0.000175	0.00392	CbGeAlD
Nilotinib—BRAF—lymph node—lung cancer	0.000173	0.00387	CbGeAlD
Nilotinib—PDGFRB—trachea—lung cancer	0.000172	0.00386	CbGeAlD
Nilotinib—EPHB3—lymph node—lung cancer	0.000172	0.00384	CbGeAlD
Nilotinib—ABL1—bronchus—lung cancer	0.000171	0.00383	CbGeAlD
Nilotinib—CA4—respiratory system—lung cancer	0.000171	0.00383	CbGeAlD
Nilotinib—EPHB6—lung—lung cancer	0.000167	0.00375	CbGeAlD
Nilotinib—PDGFRB—cardiac atrium—lung cancer	0.000162	0.00363	CbGeAlD
Nilotinib—PDGFRA—lung—lung cancer	0.000159	0.00355	CbGeAlD
Nilotinib—HCK—lymph node—lung cancer	0.000158	0.00353	CbGeAlD
Nilotinib—ABL2—lymph node—lung cancer	0.000157	0.00351	CbGeAlD
Nilotinib—CSF1R—bone marrow—lung cancer	0.000154	0.00345	CbGeAlD
Nilotinib—ABL1—trachea—lung cancer	0.000154	0.00344	CbGeAlD
Nilotinib—CA12—lung—lung cancer	0.000147	0.00328	CbGeAlD
Nilotinib—ABL1—cardiac atrium—lung cancer	0.000144	0.00323	CbGeAlD
Nilotinib—EPHA4—lymph node—lung cancer	0.000143	0.00321	CbGeAlD
Nilotinib—MAP2K5—lung—lung cancer	0.000143	0.00321	CbGeAlD
Nilotinib—CA2—respiratory system—lung cancer	0.000142	0.00317	CbGeAlD
Nilotinib—CA3—lymph node—lung cancer	0.000141	0.00317	CbGeAlD
Nilotinib—KIT—bone marrow—lung cancer	0.00014	0.00314	CbGeAlD
Nilotinib—CSF1R—lung—lung cancer	0.00014	0.00313	CbGeAlD
Nilotinib—Imatinib—ABCG2—lung cancer	0.000138	0.0488	CrCbGaD
Nilotinib—PDGFRB—bone marrow—lung cancer	0.000137	0.00306	CbGeAlD
Nilotinib—MAPK14—lymph node—lung cancer	0.000132	0.00296	CbGeAlD
Nilotinib—LCK—lymph node—lung cancer	0.000132	0.00295	CbGeAlD
Nilotinib—FGR—lymph node—lung cancer	0.000132	0.00295	CbGeAlD
Nilotinib—CA1—bone marrow—lung cancer	0.000128	0.00287	CbGeAlD
Nilotinib—KIT—lung—lung cancer	0.000127	0.00284	CbGeAlD
Nilotinib—CA4—trachea—lung cancer	0.000126	0.00283	CbGeAlD
Nilotinib—EPHB4—lymph node—lung cancer	0.000125	0.0028	CbGeAlD
Nilotinib—PDGFRB—lung—lung cancer	0.000124	0.00278	CbGeAlD
Nilotinib—EPHA2—lymph node—lung cancer	0.000123	0.00275	CbGeAlD
Nilotinib—ABL1—bone marrow—lung cancer	0.000122	0.00273	CbGeAlD
Nilotinib—CYP2B6—respiratory system—lung cancer	0.000121	0.00271	CbGeAlD
Nilotinib—TEK—lymph node—lung cancer	0.00012	0.00268	CbGeAlD
Nilotinib—CA4—cardiac atrium—lung cancer	0.000119	0.00266	CbGeAlD
Nilotinib—CA2—epithelium—lung cancer	0.000118	0.00265	CbGeAlD
Nilotinib—CA2—bronchus—lung cancer	0.000117	0.00261	CbGeAlD
Nilotinib—CA1—lung—lung cancer	0.000116	0.0026	CbGeAlD
Nilotinib—EPHB6—lymph node—lung cancer	0.000115	0.00256	CbGeAlD
Nilotinib—ABL1—lung—lung cancer	0.00011	0.00247	CbGeAlD
Nilotinib—PDGFRA—lymph node—lung cancer	0.000109	0.00243	CbGeAlD
Nilotinib—CA2—trachea—lung cancer	0.000105	0.00234	CbGeAlD
Nilotinib—CA4—bone marrow—lung cancer	0.0001	0.00224	CbGeAlD
Nilotinib—CYP2B6—bronchus—lung cancer	9.96e-05	0.00223	CbGeAlD
Nilotinib—CA2—cardiac atrium—lung cancer	9.83e-05	0.0022	CbGeAlD
Nilotinib—MAP2K5—lymph node—lung cancer	9.79e-05	0.00219	CbGeAlD
Nilotinib—CSF1R—lymph node—lung cancer	9.56e-05	0.00214	CbGeAlD
Nilotinib—Ponatinib—ABCB1—lung cancer	9.33e-05	0.033	CrCbGaD
Nilotinib—CA4—lung—lung cancer	9.07e-05	0.00203	CbGeAlD
Nilotinib—KIT—lymph node—lung cancer	8.68e-05	0.00194	CbGeAlD
Nilotinib—PDGFRB—lymph node—lung cancer	8.48e-05	0.0019	CbGeAlD
Nilotinib—CA2—bone marrow—lung cancer	8.3e-05	0.00186	CbGeAlD
Nilotinib—CA1—lymph node—lung cancer	7.94e-05	0.00178	CbGeAlD
Nilotinib—ABCG2—bone marrow—lung cancer	7.69e-05	0.00172	CbGeAlD
Nilotinib—ABL1—lymph node—lung cancer	7.56e-05	0.00169	CbGeAlD
Nilotinib—CA2—lung—lung cancer	7.52e-05	0.00168	CbGeAlD
Nilotinib—ABCG2—lung—lung cancer	6.97e-05	0.00156	CbGeAlD
Nilotinib—ABL1—Idarubicin—Doxorubicin—lung cancer	6.55e-05	0.0397	CbGdCrCtD
Nilotinib—ABL1—Epirubicin—Doxorubicin—lung cancer	6.55e-05	0.0397	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Doxorubicin—lung cancer	6.55e-05	0.0397	CbGdCrCtD
Nilotinib—ABCB1—respiratory system—lung cancer	6.47e-05	0.00145	CbGeAlD
Nilotinib—CYP2B6—lung—lung cancer	6.43e-05	0.00144	CbGeAlD
Nilotinib—CA4—lymph node—lung cancer	6.2e-05	0.00139	CbGeAlD
Nilotinib—Imatinib—ALB—lung cancer	6.02e-05	0.0213	CrCbGaD
Nilotinib—Imatinib—ABCB1—lung cancer	5.74e-05	0.0203	CrCbGaD
Nilotinib—ABCB1—epithelium—lung cancer	5.41e-05	0.00121	CbGeAlD
Nilotinib—CA2—lymph node—lung cancer	5.14e-05	0.00115	CbGeAlD
Nilotinib—ABCB1—trachea—lung cancer	4.78e-05	0.00107	CbGeAlD
Nilotinib—ABCG2—lymph node—lung cancer	4.76e-05	0.00107	CbGeAlD
Nilotinib—ABCB1—bone marrow—lung cancer	3.79e-05	0.000849	CbGeAlD
Nilotinib—ABCB1—lung—lung cancer	3.44e-05	0.000769	CbGeAlD
Nilotinib—ABCB1—lymph node—lung cancer	2.35e-05	0.000526	CbGeAlD
Nilotinib—Asthenia—Gemcitabine—lung cancer	1.95e-05	0.000208	CcSEcCtD
Nilotinib—Pain—Paclitaxel—lung cancer	1.95e-05	0.000208	CcSEcCtD
Nilotinib—Constipation—Paclitaxel—lung cancer	1.95e-05	0.000208	CcSEcCtD
Nilotinib—Confusional state—Docetaxel—lung cancer	1.94e-05	0.000208	CcSEcCtD
Nilotinib—Pharyngitis—Methotrexate—lung cancer	1.94e-05	0.000207	CcSEcCtD
Nilotinib—Urinary tract disorder—Methotrexate—lung cancer	1.93e-05	0.000206	CcSEcCtD
Nilotinib—Photosensitivity reaction—Doxorubicin—lung cancer	1.93e-05	0.000206	CcSEcCtD
Nilotinib—Oedema—Docetaxel—lung cancer	1.93e-05	0.000206	CcSEcCtD
Nilotinib—Weight increased—Doxorubicin—lung cancer	1.93e-05	0.000206	CcSEcCtD
Nilotinib—Pruritus—Gemcitabine—lung cancer	1.92e-05	0.000205	CcSEcCtD
Nilotinib—Urethral disorder—Methotrexate—lung cancer	1.92e-05	0.000205	CcSEcCtD
Nilotinib—Infection—Docetaxel—lung cancer	1.92e-05	0.000205	CcSEcCtD
Nilotinib—Weight decreased—Doxorubicin—lung cancer	1.91e-05	0.000205	CcSEcCtD
Nilotinib—Feeling abnormal—Etoposide—lung cancer	1.91e-05	0.000204	CcSEcCtD
Nilotinib—Hyperglycaemia—Doxorubicin—lung cancer	1.91e-05	0.000204	CcSEcCtD
Nilotinib—Diarrhoea—Irinotecan—lung cancer	1.91e-05	0.000204	CcSEcCtD
Nilotinib—Pneumonia—Doxorubicin—lung cancer	1.9e-05	0.000203	CcSEcCtD
Nilotinib—Gastrointestinal pain—Etoposide—lung cancer	1.9e-05	0.000203	CcSEcCtD
Nilotinib—Shock—Docetaxel—lung cancer	1.9e-05	0.000203	CcSEcCtD
Nilotinib—Nervous system disorder—Docetaxel—lung cancer	1.89e-05	0.000202	CcSEcCtD
Nilotinib—Thrombocytopenia—Docetaxel—lung cancer	1.89e-05	0.000202	CcSEcCtD
Nilotinib—Infestation NOS—Doxorubicin—lung cancer	1.89e-05	0.000202	CcSEcCtD
Nilotinib—Infestation—Doxorubicin—lung cancer	1.89e-05	0.000202	CcSEcCtD
Nilotinib—Visual impairment—Methotrexate—lung cancer	1.89e-05	0.000201	CcSEcCtD
Nilotinib—Tachycardia—Docetaxel—lung cancer	1.88e-05	0.000201	CcSEcCtD
Nilotinib—Feeling abnormal—Paclitaxel—lung cancer	1.87e-05	0.0002	CcSEcCtD
Nilotinib—Skin disorder—Docetaxel—lung cancer	1.87e-05	0.0002	CcSEcCtD
Nilotinib—Hypersensitivity—Cisplatin—lung cancer	1.87e-05	0.000199	CcSEcCtD
Nilotinib—Gastrointestinal pain—Paclitaxel—lung cancer	1.86e-05	0.000199	CcSEcCtD
Nilotinib—Diarrhoea—Gemcitabine—lung cancer	1.86e-05	0.000199	CcSEcCtD
Nilotinib—Renal failure—Doxorubicin—lung cancer	1.85e-05	0.000198	CcSEcCtD
Nilotinib—Erythema multiforme—Methotrexate—lung cancer	1.85e-05	0.000198	CcSEcCtD
Nilotinib—Neuropathy peripheral—Doxorubicin—lung cancer	1.85e-05	0.000198	CcSEcCtD
Nilotinib—Dizziness—Irinotecan—lung cancer	1.84e-05	0.000197	CcSEcCtD
Nilotinib—Urticaria—Etoposide—lung cancer	1.84e-05	0.000197	CcSEcCtD
Nilotinib—Stomatitis—Doxorubicin—lung cancer	1.84e-05	0.000197	CcSEcCtD
Nilotinib—Jaundice—Doxorubicin—lung cancer	1.84e-05	0.000197	CcSEcCtD
Nilotinib—Anorexia—Docetaxel—lung cancer	1.84e-05	0.000196	CcSEcCtD
Nilotinib—Abdominal pain—Etoposide—lung cancer	1.83e-05	0.000196	CcSEcCtD
Nilotinib—Body temperature increased—Etoposide—lung cancer	1.83e-05	0.000196	CcSEcCtD
Nilotinib—Urinary tract infection—Doxorubicin—lung cancer	1.83e-05	0.000196	CcSEcCtD
Nilotinib—Conjunctivitis—Doxorubicin—lung cancer	1.83e-05	0.000196	CcSEcCtD
Nilotinib—Eye disorder—Methotrexate—lung cancer	1.83e-05	0.000195	CcSEcCtD
Nilotinib—Tinnitus—Methotrexate—lung cancer	1.82e-05	0.000195	CcSEcCtD
Nilotinib—Asthenia—Cisplatin—lung cancer	1.82e-05	0.000194	CcSEcCtD
Nilotinib—Cardiac disorder—Methotrexate—lung cancer	1.82e-05	0.000194	CcSEcCtD
Nilotinib—Urticaria—Paclitaxel—lung cancer	1.81e-05	0.000193	CcSEcCtD
Nilotinib—Hypotension—Docetaxel—lung cancer	1.8e-05	0.000193	CcSEcCtD
Nilotinib—Haematuria—Doxorubicin—lung cancer	1.8e-05	0.000192	CcSEcCtD
Nilotinib—Abdominal pain—Paclitaxel—lung cancer	1.8e-05	0.000192	CcSEcCtD
Nilotinib—Body temperature increased—Paclitaxel—lung cancer	1.8e-05	0.000192	CcSEcCtD
Nilotinib—Hepatobiliary disease—Doxorubicin—lung cancer	1.78e-05	0.000191	CcSEcCtD
Nilotinib—Epistaxis—Doxorubicin—lung cancer	1.78e-05	0.00019	CcSEcCtD
Nilotinib—Angiopathy—Methotrexate—lung cancer	1.77e-05	0.00019	CcSEcCtD
Nilotinib—Vomiting—Irinotecan—lung cancer	1.77e-05	0.00019	CcSEcCtD
Nilotinib—Immune system disorder—Methotrexate—lung cancer	1.77e-05	0.000189	CcSEcCtD
Nilotinib—Mediastinal disorder—Methotrexate—lung cancer	1.76e-05	0.000188	CcSEcCtD
Nilotinib—Rash—Irinotecan—lung cancer	1.76e-05	0.000188	CcSEcCtD
Nilotinib—Dermatitis—Irinotecan—lung cancer	1.76e-05	0.000188	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Docetaxel—lung cancer	1.76e-05	0.000188	CcSEcCtD
Nilotinib—Chills—Methotrexate—lung cancer	1.76e-05	0.000188	CcSEcCtD
Nilotinib—Headache—Irinotecan—lung cancer	1.75e-05	0.000187	CcSEcCtD
Nilotinib—Insomnia—Docetaxel—lung cancer	1.74e-05	0.000186	CcSEcCtD
Nilotinib—Diarrhoea—Cisplatin—lung cancer	1.73e-05	0.000185	CcSEcCtD
Nilotinib—Paraesthesia—Docetaxel—lung cancer	1.73e-05	0.000185	CcSEcCtD
Nilotinib—Alopecia—Methotrexate—lung cancer	1.73e-05	0.000185	CcSEcCtD
Nilotinib—Vomiting—Gemcitabine—lung cancer	1.73e-05	0.000185	CcSEcCtD
Nilotinib—Bradycardia—Doxorubicin—lung cancer	1.72e-05	0.000184	CcSEcCtD
Nilotinib—Dyspnoea—Docetaxel—lung cancer	1.72e-05	0.000184	CcSEcCtD
Nilotinib—Mental disorder—Methotrexate—lung cancer	1.71e-05	0.000183	CcSEcCtD
Nilotinib—Rash—Gemcitabine—lung cancer	1.71e-05	0.000183	CcSEcCtD
Nilotinib—Dermatitis—Gemcitabine—lung cancer	1.71e-05	0.000183	CcSEcCtD
Nilotinib—Hypersensitivity—Etoposide—lung cancer	1.71e-05	0.000183	CcSEcCtD
Nilotinib—Malnutrition—Methotrexate—lung cancer	1.7e-05	0.000182	CcSEcCtD
Nilotinib—Erythema—Methotrexate—lung cancer	1.7e-05	0.000182	CcSEcCtD
Nilotinib—Haemoglobin—Doxorubicin—lung cancer	1.7e-05	0.000182	CcSEcCtD
Nilotinib—Headache—Gemcitabine—lung cancer	1.7e-05	0.000182	CcSEcCtD
Nilotinib—Rhinitis—Doxorubicin—lung cancer	1.7e-05	0.000181	CcSEcCtD
Nilotinib—Dyspepsia—Docetaxel—lung cancer	1.7e-05	0.000181	CcSEcCtD
Nilotinib—Haemorrhage—Doxorubicin—lung cancer	1.69e-05	0.000181	CcSEcCtD
Nilotinib—Hepatitis—Doxorubicin—lung cancer	1.69e-05	0.000181	CcSEcCtD
Nilotinib—Hypoaesthesia—Doxorubicin—lung cancer	1.69e-05	0.00018	CcSEcCtD
Nilotinib—Pharyngitis—Doxorubicin—lung cancer	1.68e-05	0.00018	CcSEcCtD
Nilotinib—Decreased appetite—Docetaxel—lung cancer	1.68e-05	0.000179	CcSEcCtD
Nilotinib—Hypersensitivity—Paclitaxel—lung cancer	1.68e-05	0.000179	CcSEcCtD
Nilotinib—Urinary tract disorder—Doxorubicin—lung cancer	1.67e-05	0.000179	CcSEcCtD
Nilotinib—Oedema peripheral—Doxorubicin—lung cancer	1.67e-05	0.000178	CcSEcCtD
Nilotinib—Dysgeusia—Methotrexate—lung cancer	1.67e-05	0.000178	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Docetaxel—lung cancer	1.66e-05	0.000178	CcSEcCtD
Nilotinib—Asthenia—Etoposide—lung cancer	1.66e-05	0.000178	CcSEcCtD
Nilotinib—Connective tissue disorder—Doxorubicin—lung cancer	1.66e-05	0.000178	CcSEcCtD
Nilotinib—Fatigue—Docetaxel—lung cancer	1.66e-05	0.000178	CcSEcCtD
Nilotinib—Urethral disorder—Doxorubicin—lung cancer	1.66e-05	0.000177	CcSEcCtD
Nilotinib—Nausea—Irinotecan—lung cancer	1.66e-05	0.000177	CcSEcCtD
Nilotinib—Pain—Docetaxel—lung cancer	1.65e-05	0.000176	CcSEcCtD
Nilotinib—Constipation—Docetaxel—lung cancer	1.65e-05	0.000176	CcSEcCtD
Nilotinib—Back pain—Methotrexate—lung cancer	1.65e-05	0.000176	CcSEcCtD
Nilotinib—Pruritus—Etoposide—lung cancer	1.64e-05	0.000175	CcSEcCtD
Nilotinib—Visual impairment—Doxorubicin—lung cancer	1.63e-05	0.000174	CcSEcCtD
Nilotinib—Asthenia—Paclitaxel—lung cancer	1.63e-05	0.000174	CcSEcCtD
Nilotinib—Nausea—Gemcitabine—lung cancer	1.61e-05	0.000172	CcSEcCtD
Nilotinib—Vomiting—Cisplatin—lung cancer	1.61e-05	0.000172	CcSEcCtD
Nilotinib—Pruritus—Paclitaxel—lung cancer	1.61e-05	0.000172	CcSEcCtD
Nilotinib—Vision blurred—Methotrexate—lung cancer	1.61e-05	0.000171	CcSEcCtD
Nilotinib—Erythema multiforme—Doxorubicin—lung cancer	1.6e-05	0.000171	CcSEcCtD
Nilotinib—Rash—Cisplatin—lung cancer	1.6e-05	0.000171	CcSEcCtD
Nilotinib—Dermatitis—Cisplatin—lung cancer	1.6e-05	0.00017	CcSEcCtD
Nilotinib—Feeling abnormal—Docetaxel—lung cancer	1.59e-05	0.00017	CcSEcCtD
Nilotinib—Diarrhoea—Etoposide—lung cancer	1.59e-05	0.00017	CcSEcCtD
Nilotinib—Eye disorder—Doxorubicin—lung cancer	1.58e-05	0.000169	CcSEcCtD
Nilotinib—Ill-defined disorder—Methotrexate—lung cancer	1.58e-05	0.000169	CcSEcCtD
Nilotinib—Tinnitus—Doxorubicin—lung cancer	1.58e-05	0.000169	CcSEcCtD
Nilotinib—Gastrointestinal pain—Docetaxel—lung cancer	1.58e-05	0.000168	CcSEcCtD
Nilotinib—Anaemia—Methotrexate—lung cancer	1.57e-05	0.000168	CcSEcCtD
Nilotinib—Flushing—Doxorubicin—lung cancer	1.57e-05	0.000168	CcSEcCtD
Nilotinib—Cardiac disorder—Doxorubicin—lung cancer	1.57e-05	0.000168	CcSEcCtD
Nilotinib—Diarrhoea—Paclitaxel—lung cancer	1.56e-05	0.000166	CcSEcCtD
Nilotinib—Angiopathy—Doxorubicin—lung cancer	1.54e-05	0.000164	CcSEcCtD
Nilotinib—Malaise—Methotrexate—lung cancer	1.54e-05	0.000164	CcSEcCtD
Nilotinib—Dizziness—Etoposide—lung cancer	1.53e-05	0.000164	CcSEcCtD
Nilotinib—Immune system disorder—Doxorubicin—lung cancer	1.53e-05	0.000163	CcSEcCtD
Nilotinib—Vertigo—Methotrexate—lung cancer	1.53e-05	0.000163	CcSEcCtD
Nilotinib—Mediastinal disorder—Doxorubicin—lung cancer	1.53e-05	0.000163	CcSEcCtD
Nilotinib—Abdominal pain—Docetaxel—lung cancer	1.52e-05	0.000163	CcSEcCtD
Nilotinib—Body temperature increased—Docetaxel—lung cancer	1.52e-05	0.000163	CcSEcCtD
Nilotinib—Leukopenia—Methotrexate—lung cancer	1.52e-05	0.000163	CcSEcCtD
Nilotinib—Chills—Doxorubicin—lung cancer	1.52e-05	0.000162	CcSEcCtD
Nilotinib—Arrhythmia—Doxorubicin—lung cancer	1.51e-05	0.000162	CcSEcCtD
Nilotinib—Dizziness—Paclitaxel—lung cancer	1.5e-05	0.000161	CcSEcCtD
Nilotinib—Nausea—Cisplatin—lung cancer	1.5e-05	0.000161	CcSEcCtD
Nilotinib—Alopecia—Doxorubicin—lung cancer	1.5e-05	0.00016	CcSEcCtD
Nilotinib—Cough—Methotrexate—lung cancer	1.49e-05	0.000159	CcSEcCtD
Nilotinib—Mental disorder—Doxorubicin—lung cancer	1.48e-05	0.000159	CcSEcCtD
Nilotinib—Vomiting—Etoposide—lung cancer	1.48e-05	0.000158	CcSEcCtD
Nilotinib—Erythema—Doxorubicin—lung cancer	1.47e-05	0.000158	CcSEcCtD
Nilotinib—Malnutrition—Doxorubicin—lung cancer	1.47e-05	0.000158	CcSEcCtD
Nilotinib—Rash—Etoposide—lung cancer	1.46e-05	0.000156	CcSEcCtD
Nilotinib—Dermatitis—Etoposide—lung cancer	1.46e-05	0.000156	CcSEcCtD
Nilotinib—Headache—Etoposide—lung cancer	1.45e-05	0.000155	CcSEcCtD
Nilotinib—Flatulence—Doxorubicin—lung cancer	1.45e-05	0.000155	CcSEcCtD
Nilotinib—Chest pain—Methotrexate—lung cancer	1.45e-05	0.000155	CcSEcCtD
Nilotinib—Arthralgia—Methotrexate—lung cancer	1.45e-05	0.000155	CcSEcCtD
Nilotinib—Myalgia—Methotrexate—lung cancer	1.45e-05	0.000155	CcSEcCtD
Nilotinib—Vomiting—Paclitaxel—lung cancer	1.45e-05	0.000155	CcSEcCtD
Nilotinib—Dysgeusia—Doxorubicin—lung cancer	1.44e-05	0.000154	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	1.44e-05	0.000154	CcSEcCtD
Nilotinib—Rash—Paclitaxel—lung cancer	1.43e-05	0.000153	CcSEcCtD
Nilotinib—Dermatitis—Paclitaxel—lung cancer	1.43e-05	0.000153	CcSEcCtD
Nilotinib—Discomfort—Methotrexate—lung cancer	1.43e-05	0.000153	CcSEcCtD
Nilotinib—Back pain—Doxorubicin—lung cancer	1.43e-05	0.000152	CcSEcCtD
Nilotinib—Headache—Paclitaxel—lung cancer	1.43e-05	0.000152	CcSEcCtD
Nilotinib—Hypersensitivity—Docetaxel—lung cancer	1.42e-05	0.000152	CcSEcCtD
Nilotinib—Muscle spasms—Doxorubicin—lung cancer	1.42e-05	0.000151	CcSEcCtD
Nilotinib—Confusional state—Methotrexate—lung cancer	1.4e-05	0.00015	CcSEcCtD
Nilotinib—Vision blurred—Doxorubicin—lung cancer	1.39e-05	0.000148	CcSEcCtD
Nilotinib—Asthenia—Docetaxel—lung cancer	1.38e-05	0.000148	CcSEcCtD
Nilotinib—Infection—Methotrexate—lung cancer	1.38e-05	0.000148	CcSEcCtD
Nilotinib—Nausea—Etoposide—lung cancer	1.38e-05	0.000147	CcSEcCtD
Nilotinib—Ill-defined disorder—Doxorubicin—lung cancer	1.37e-05	0.000146	CcSEcCtD
Nilotinib—Pruritus—Docetaxel—lung cancer	1.36e-05	0.000146	CcSEcCtD
Nilotinib—Nervous system disorder—Methotrexate—lung cancer	1.36e-05	0.000146	CcSEcCtD
Nilotinib—Anaemia—Doxorubicin—lung cancer	1.36e-05	0.000146	CcSEcCtD
Nilotinib—Thrombocytopenia—Methotrexate—lung cancer	1.36e-05	0.000145	CcSEcCtD
Nilotinib—Nausea—Paclitaxel—lung cancer	1.35e-05	0.000144	CcSEcCtD
Nilotinib—Skin disorder—Methotrexate—lung cancer	1.35e-05	0.000144	CcSEcCtD
Nilotinib—Hyperhidrosis—Methotrexate—lung cancer	1.34e-05	0.000144	CcSEcCtD
Nilotinib—Malaise—Doxorubicin—lung cancer	1.33e-05	0.000142	CcSEcCtD
Nilotinib—Vertigo—Doxorubicin—lung cancer	1.32e-05	0.000142	CcSEcCtD
Nilotinib—Anorexia—Methotrexate—lung cancer	1.32e-05	0.000142	CcSEcCtD
Nilotinib—Syncope—Doxorubicin—lung cancer	1.32e-05	0.000141	CcSEcCtD
Nilotinib—Leukopenia—Doxorubicin—lung cancer	1.32e-05	0.000141	CcSEcCtD
Nilotinib—Diarrhoea—Docetaxel—lung cancer	1.32e-05	0.000141	CcSEcCtD
Nilotinib—Palpitations—Doxorubicin—lung cancer	1.3e-05	0.000139	CcSEcCtD
Nilotinib—Hypotension—Methotrexate—lung cancer	1.3e-05	0.000139	CcSEcCtD
Nilotinib—Loss of consciousness—Doxorubicin—lung cancer	1.3e-05	0.000138	CcSEcCtD
Nilotinib—Cough—Doxorubicin—lung cancer	1.29e-05	0.000137	CcSEcCtD
Nilotinib—Dizziness—Docetaxel—lung cancer	1.28e-05	0.000136	CcSEcCtD
Nilotinib—Hypertension—Doxorubicin—lung cancer	1.27e-05	0.000136	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methotrexate—lung cancer	1.27e-05	0.000135	CcSEcCtD
Nilotinib—Insomnia—Methotrexate—lung cancer	1.26e-05	0.000134	CcSEcCtD
Nilotinib—Myalgia—Doxorubicin—lung cancer	1.26e-05	0.000134	CcSEcCtD
Nilotinib—Arthralgia—Doxorubicin—lung cancer	1.26e-05	0.000134	CcSEcCtD
Nilotinib—Chest pain—Doxorubicin—lung cancer	1.26e-05	0.000134	CcSEcCtD
Nilotinib—Anxiety—Doxorubicin—lung cancer	1.25e-05	0.000134	CcSEcCtD
Nilotinib—Paraesthesia—Methotrexate—lung cancer	1.25e-05	0.000133	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	1.25e-05	0.000133	CcSEcCtD
Nilotinib—Discomfort—Doxorubicin—lung cancer	1.24e-05	0.000133	CcSEcCtD
Nilotinib—Dyspnoea—Methotrexate—lung cancer	1.24e-05	0.000132	CcSEcCtD
Nilotinib—Dry mouth—Doxorubicin—lung cancer	1.23e-05	0.000131	CcSEcCtD
Nilotinib—Vomiting—Docetaxel—lung cancer	1.23e-05	0.000131	CcSEcCtD
Nilotinib—Dyspepsia—Methotrexate—lung cancer	1.22e-05	0.000131	CcSEcCtD
Nilotinib—Rash—Docetaxel—lung cancer	1.22e-05	0.00013	CcSEcCtD
Nilotinib—Dermatitis—Docetaxel—lung cancer	1.21e-05	0.00013	CcSEcCtD
Nilotinib—Confusional state—Doxorubicin—lung cancer	1.21e-05	0.00013	CcSEcCtD
Nilotinib—Decreased appetite—Methotrexate—lung cancer	1.21e-05	0.000129	CcSEcCtD
Nilotinib—Headache—Docetaxel—lung cancer	1.21e-05	0.000129	CcSEcCtD
Nilotinib—Oedema—Doxorubicin—lung cancer	1.2e-05	0.000129	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Methotrexate—lung cancer	1.2e-05	0.000128	CcSEcCtD
Nilotinib—Fatigue—Methotrexate—lung cancer	1.2e-05	0.000128	CcSEcCtD
Nilotinib—Infection—Doxorubicin—lung cancer	1.2e-05	0.000128	CcSEcCtD
Nilotinib—Pain—Methotrexate—lung cancer	1.19e-05	0.000127	CcSEcCtD
Nilotinib—Shock—Doxorubicin—lung cancer	1.18e-05	0.000127	CcSEcCtD
Nilotinib—Nervous system disorder—Doxorubicin—lung cancer	1.18e-05	0.000126	CcSEcCtD
Nilotinib—Thrombocytopenia—Doxorubicin—lung cancer	1.18e-05	0.000126	CcSEcCtD
Nilotinib—Tachycardia—Doxorubicin—lung cancer	1.17e-05	0.000126	CcSEcCtD
Nilotinib—Skin disorder—Doxorubicin—lung cancer	1.17e-05	0.000125	CcSEcCtD
Nilotinib—Hyperhidrosis—Doxorubicin—lung cancer	1.16e-05	0.000124	CcSEcCtD
Nilotinib—Anorexia—Doxorubicin—lung cancer	1.15e-05	0.000123	CcSEcCtD
Nilotinib—Nausea—Docetaxel—lung cancer	1.15e-05	0.000122	CcSEcCtD
Nilotinib—Feeling abnormal—Methotrexate—lung cancer	1.15e-05	0.000122	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methotrexate—lung cancer	1.14e-05	0.000121	CcSEcCtD
Nilotinib—Hypotension—Doxorubicin—lung cancer	1.12e-05	0.00012	CcSEcCtD
Nilotinib—Urticaria—Methotrexate—lung cancer	1.1e-05	0.000118	CcSEcCtD
Nilotinib—Body temperature increased—Methotrexate—lung cancer	1.1e-05	0.000117	CcSEcCtD
Nilotinib—Abdominal pain—Methotrexate—lung cancer	1.1e-05	0.000117	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Doxorubicin—lung cancer	1.1e-05	0.000117	CcSEcCtD
Nilotinib—Insomnia—Doxorubicin—lung cancer	1.09e-05	0.000116	CcSEcCtD
Nilotinib—Paraesthesia—Doxorubicin—lung cancer	1.08e-05	0.000115	CcSEcCtD
Nilotinib—Dyspnoea—Doxorubicin—lung cancer	1.07e-05	0.000115	CcSEcCtD
Nilotinib—Dyspepsia—Doxorubicin—lung cancer	1.06e-05	0.000113	CcSEcCtD
Nilotinib—Decreased appetite—Doxorubicin—lung cancer	1.05e-05	0.000112	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Doxorubicin—lung cancer	1.04e-05	0.000111	CcSEcCtD
Nilotinib—Fatigue—Doxorubicin—lung cancer	1.04e-05	0.000111	CcSEcCtD
Nilotinib—Constipation—Doxorubicin—lung cancer	1.03e-05	0.00011	CcSEcCtD
Nilotinib—Pain—Doxorubicin—lung cancer	1.03e-05	0.00011	CcSEcCtD
Nilotinib—Hypersensitivity—Methotrexate—lung cancer	1.02e-05	0.000109	CcSEcCtD
Nilotinib—Asthenia—Methotrexate—lung cancer	9.97e-06	0.000107	CcSEcCtD
Nilotinib—Feeling abnormal—Doxorubicin—lung cancer	9.92e-06	0.000106	CcSEcCtD
Nilotinib—Gastrointestinal pain—Doxorubicin—lung cancer	9.84e-06	0.000105	CcSEcCtD
Nilotinib—Pruritus—Methotrexate—lung cancer	9.83e-06	0.000105	CcSEcCtD
Nilotinib—Urticaria—Doxorubicin—lung cancer	9.56e-06	0.000102	CcSEcCtD
Nilotinib—Abdominal pain—Doxorubicin—lung cancer	9.51e-06	0.000102	CcSEcCtD
Nilotinib—Body temperature increased—Doxorubicin—lung cancer	9.51e-06	0.000102	CcSEcCtD
Nilotinib—Diarrhoea—Methotrexate—lung cancer	9.51e-06	0.000102	CcSEcCtD
Nilotinib—Dizziness—Methotrexate—lung cancer	9.19e-06	9.82e-05	CcSEcCtD
Nilotinib—Hypersensitivity—Doxorubicin—lung cancer	8.87e-06	9.47e-05	CcSEcCtD
Nilotinib—Vomiting—Methotrexate—lung cancer	8.84e-06	9.44e-05	CcSEcCtD
Nilotinib—Rash—Methotrexate—lung cancer	8.76e-06	9.36e-05	CcSEcCtD
Nilotinib—Dermatitis—Methotrexate—lung cancer	8.76e-06	9.36e-05	CcSEcCtD
Nilotinib—Headache—Methotrexate—lung cancer	8.71e-06	9.3e-05	CcSEcCtD
Nilotinib—Asthenia—Doxorubicin—lung cancer	8.64e-06	9.23e-05	CcSEcCtD
Nilotinib—Pruritus—Doxorubicin—lung cancer	8.52e-06	9.1e-05	CcSEcCtD
Nilotinib—Nausea—Methotrexate—lung cancer	8.26e-06	8.82e-05	CcSEcCtD
Nilotinib—Diarrhoea—Doxorubicin—lung cancer	8.23e-06	8.8e-05	CcSEcCtD
Nilotinib—Dizziness—Doxorubicin—lung cancer	7.96e-06	8.5e-05	CcSEcCtD
Nilotinib—Vomiting—Doxorubicin—lung cancer	7.65e-06	8.18e-05	CcSEcCtD
Nilotinib—Rash—Doxorubicin—lung cancer	7.59e-06	8.11e-05	CcSEcCtD
Nilotinib—Dermatitis—Doxorubicin—lung cancer	7.58e-06	8.1e-05	CcSEcCtD
Nilotinib—Headache—Doxorubicin—lung cancer	7.54e-06	8.06e-05	CcSEcCtD
Nilotinib—Nausea—Doxorubicin—lung cancer	7.15e-06	7.64e-05	CcSEcCtD
Nilotinib—PDGFRB—Signaling Pathways—PTEN—lung cancer	3.97e-07	3.82e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KRAS—lung cancer	3.97e-07	3.81e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—STAT3—lung cancer	3.95e-07	3.79e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ABCB1—lung cancer	3.94e-07	3.79e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NRAS—lung cancer	3.94e-07	3.78e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—lung cancer	3.94e-07	3.78e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—AKT1—lung cancer	3.93e-07	3.78e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KRAS—lung cancer	3.93e-07	3.78e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTT1—lung cancer	3.93e-07	3.78e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—HRAS—lung cancer	3.93e-07	3.77e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CASP3—lung cancer	3.93e-07	3.77e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2—lung cancer	3.92e-07	3.77e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—lung cancer	3.91e-07	3.76e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ABCB1—lung cancer	3.91e-07	3.76e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HRAS—lung cancer	3.91e-07	3.76e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CDKN1A—lung cancer	3.9e-07	3.75e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—POMC—lung cancer	3.89e-07	3.74e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MAPK3—lung cancer	3.89e-07	3.74e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PTEN—lung cancer	3.89e-07	3.74e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP2A6—lung cancer	3.88e-07	3.73e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GCLC—lung cancer	3.88e-07	3.73e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TYMS—lung cancer	3.87e-07	3.72e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MYC—lung cancer	3.87e-07	3.72e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—lung cancer	3.85e-07	3.7e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP1A1—lung cancer	3.85e-07	3.7e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TYMS—lung cancer	3.84e-07	3.69e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—lung cancer	3.84e-07	3.69e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—AKT1—lung cancer	3.84e-07	3.68e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTM1—lung cancer	3.83e-07	3.68e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCND1—lung cancer	3.82e-07	3.67e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ERCC2—lung cancer	3.82e-07	3.67e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—JUN—lung cancer	3.81e-07	3.66e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTM1—lung cancer	3.8e-07	3.65e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MDM2—lung cancer	3.79e-07	3.64e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—APOA1—lung cancer	3.79e-07	3.64e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CREBBP—lung cancer	3.79e-07	3.64e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EP300—lung cancer	3.79e-07	3.64e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—lung cancer	3.79e-07	3.64e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—KRAS—lung cancer	3.79e-07	3.64e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MYC—lung cancer	3.78e-07	3.64e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RAF1—lung cancer	3.78e-07	3.63e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MAPK3—lung cancer	3.77e-07	3.62e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—lung cancer	3.76e-07	3.61e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—lung cancer	3.74e-07	3.59e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ERBB2—lung cancer	3.74e-07	3.59e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKT1—lung cancer	3.74e-07	3.59e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HRAS—lung cancer	3.72e-07	3.58e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EP300—lung cancer	3.71e-07	3.56e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—lung cancer	3.71e-07	3.56e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—HRAS—lung cancer	3.7e-07	3.56e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—lung cancer	3.7e-07	3.56e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDKN1A—lung cancer	3.7e-07	3.55e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTEN—lung cancer	3.69e-07	3.55e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CB—lung cancer	3.69e-07	3.55e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MTOR—lung cancer	3.69e-07	3.55e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PTEN—lung cancer	3.69e-07	3.54e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SRC—lung cancer	3.69e-07	3.54e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ENO1—lung cancer	3.68e-07	3.54e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MYC—lung cancer	3.67e-07	3.52e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PIK3CA—lung cancer	3.65e-07	3.5e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	3.63e-07	3.49e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKT1—lung cancer	3.63e-07	3.49e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP1A1—lung cancer	3.63e-07	3.49e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PIK3CA—lung cancer	3.61e-07	3.47e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SRC—lung cancer	3.61e-07	3.47e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ERCC2—lung cancer	3.6e-07	3.46e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP1A1—lung cancer	3.6e-07	3.46e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CD—lung cancer	3.6e-07	3.45e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—lung cancer	3.59e-07	3.45e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—lung cancer	3.59e-07	3.44e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—KRAS—lung cancer	3.58e-07	3.44e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ERCC2—lung cancer	3.57e-07	3.43e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—lung cancer	3.56e-07	3.42e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—STAT3—lung cancer	3.55e-07	3.41e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKT1—lung cancer	3.55e-07	3.41e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ALB—lung cancer	3.55e-07	3.41e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL8—lung cancer	3.55e-07	3.41e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NRAS—lung cancer	3.55e-07	3.41e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—lung cancer	3.55e-07	3.41e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—AKT1—lung cancer	3.54e-07	3.4e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—lung cancer	3.53e-07	3.39e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—EP300—lung cancer	3.52e-07	3.39e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EP300—lung cancer	3.52e-07	3.38e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—lung cancer	3.51e-07	3.38e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—KRAS—lung cancer	3.5e-07	3.36e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—lung cancer	3.49e-07	3.36e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—PIK3CA—lung cancer	3.48e-07	3.34e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—STAT3—lung cancer	3.48e-07	3.34e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NRAS—lung cancer	3.47e-07	3.33e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—AKT1—lung cancer	3.47e-07	3.33e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CG—lung cancer	3.46e-07	3.33e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—AKT1—lung cancer	3.45e-07	3.32e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SRC—lung cancer	3.42e-07	3.29e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK3—lung cancer	3.4e-07	3.26e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CASP3—lung cancer	3.39e-07	3.26e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—lung cancer	3.39e-07	3.26e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KRAS—lung cancer	3.39e-07	3.25e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HRAS—lung cancer	3.37e-07	3.24e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HRAS—lung cancer	3.34e-07	3.21e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—lung cancer	3.33e-07	3.2e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK3—lung cancer	3.32e-07	3.19e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOA1—lung cancer	3.3e-07	3.17e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCND1—lung cancer	3.3e-07	3.17e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP2E1—lung cancer	3.3e-07	3.17e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MYC—lung cancer	3.3e-07	3.17e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—STAT3—lung cancer	3.3e-07	3.17e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—JUN—lung cancer	3.3e-07	3.17e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—POMC—lung cancer	3.3e-07	3.17e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NRAS—lung cancer	3.29e-07	3.16e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—AKT1—lung cancer	3.29e-07	3.16e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PIK3CA—lung cancer	3.29e-07	3.16e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT1—lung cancer	3.27e-07	3.14e-06	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—AKT1—lung cancer	3.27e-07	3.14e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NQO1—lung cancer	3.27e-07	3.14e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MYC—lung cancer	3.23e-07	3.11e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—lung cancer	3.23e-07	3.1e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—lung cancer	3.23e-07	3.1e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—HRAS—lung cancer	3.22e-07	3.09e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—PIK3CA—lung cancer	3.21e-07	3.09e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CREBBP—lung cancer	3.21e-07	3.08e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—lung cancer	3.21e-07	3.08e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—lung cancer	3.2e-07	3.07e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN1A—lung cancer	3.2e-07	3.07e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PTEN—lung cancer	3.19e-07	3.06e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—lung cancer	3.18e-07	3.06e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—lung cancer	3.16e-07	3.04e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK3—lung cancer	3.15e-07	3.03e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CB—lung cancer	3.13e-07	3.01e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOA1—lung cancer	3.11e-07	2.99e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PIK3CA—lung cancer	3.11e-07	2.99e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—lung cancer	3.11e-07	2.98e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOA1—lung cancer	3.09e-07	2.97e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—lung cancer	3.08e-07	2.96e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PIK3CA—lung cancer	3.07e-07	2.95e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MYC—lung cancer	3.07e-07	2.94e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KRAS—lung cancer	3.05e-07	2.93e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CD—lung cancer	3.04e-07	2.92e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HRAS—lung cancer	3.04e-07	2.92e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EP300—lung cancer	3.04e-07	2.92e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CG—lung cancer	3.02e-07	2.9e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—lung cancer	3.01e-07	2.89e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ALB—lung cancer	3.01e-07	2.89e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—lung cancer	3e-07	2.88e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KRAS—lung cancer	2.99e-07	2.87e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT1—lung cancer	2.98e-07	2.86e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—HRAS—lung cancer	2.97e-07	2.86e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SRC—lung cancer	2.96e-07	2.84e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.96e-07	2.84e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT1—lung cancer	2.95e-07	2.83e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—STK11—lung cancer	2.94e-07	2.83e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—lung cancer	2.91e-07	2.8e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—lung cancer	2.88e-07	2.77e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HRAS—lung cancer	2.88e-07	2.77e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—POMC—lung cancer	2.87e-07	2.76e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—STAT3—lung cancer	2.85e-07	2.74e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NRAS—lung cancer	2.85e-07	2.73e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—lung cancer	2.84e-07	2.73e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CG—lung cancer	2.84e-07	2.73e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT1—lung cancer	2.84e-07	2.73e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KRAS—lung cancer	2.83e-07	2.72e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CG—lung cancer	2.82e-07	2.71e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PIK3CA—lung cancer	2.8e-07	2.69e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CREBBP—lung cancer	2.8e-07	2.69e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—lung cancer	2.76e-07	2.65e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PIK3CA—lung cancer	2.74e-07	2.64e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK3—lung cancer	2.72e-07	2.62e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTP1—lung cancer	2.72e-07	2.62e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—lung cancer	2.71e-07	2.61e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTEN—lung cancer	2.71e-07	2.6e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—POMC—lung cancer	2.71e-07	2.6e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT1—lung cancer	2.69e-07	2.58e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—POMC—lung cancer	2.68e-07	2.58e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—lung cancer	2.66e-07	2.55e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CB—lung cancer	2.65e-07	2.55e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CD—lung cancer	2.65e-07	2.55e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CAT—lung cancer	2.65e-07	2.55e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MYC—lung cancer	2.65e-07	2.55e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CREBBP—lung cancer	2.64e-07	2.53e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—lung cancer	2.63e-07	2.53e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT1—lung cancer	2.62e-07	2.52e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALB—lung cancer	2.62e-07	2.52e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CREBBP—lung cancer	2.61e-07	2.51e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PIK3CA—lung cancer	2.61e-07	2.5e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PIK3CA—lung cancer	2.6e-07	2.5e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HRAS—lung cancer	2.59e-07	2.49e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—lung cancer	2.59e-07	2.49e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—EP300—lung cancer	2.58e-07	2.48e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ABCB1—lung cancer	2.58e-07	2.48e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT1—lung cancer	2.54e-07	2.44e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HRAS—lung cancer	2.54e-07	2.44e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TYMS—lung cancer	2.53e-07	2.43e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—lung cancer	2.52e-07	2.42e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AKT1—lung cancer	2.51e-07	2.41e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTM1—lung cancer	2.5e-07	2.4e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CD—lung cancer	2.5e-07	2.4e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—lung cancer	2.48e-07	2.39e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CD—lung cancer	2.48e-07	2.38e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALB—lung cancer	2.47e-07	2.37e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KRAS—lung cancer	2.45e-07	2.35e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALB—lung cancer	2.45e-07	2.35e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—lung cancer	2.43e-07	2.34e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HRAS—lung cancer	2.41e-07	2.31e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP1A1—lung cancer	2.37e-07	2.28e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ERCC2—lung cancer	2.35e-07	2.26e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CB—lung cancer	2.31e-07	2.22e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—lung cancer	2.3e-07	2.21e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTEN—lung cancer	2.29e-07	2.2e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—lung cancer	2.29e-07	2.2e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT1—lung cancer	2.29e-07	2.2e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CA—lung cancer	2.25e-07	2.16e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT1—lung cancer	2.24e-07	2.15e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—EP300—lung cancer	2.19e-07	2.1e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CB—lung cancer	2.18e-07	2.09e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—lung cancer	2.18e-07	2.09e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CB—lung cancer	2.16e-07	2.07e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—lung cancer	2.16e-07	2.07e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—lung cancer	2.14e-07	2.06e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AKT1—lung cancer	2.13e-07	2.05e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT1—lung cancer	2.13e-07	2.04e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HRAS—lung cancer	2.08e-07	2e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOA1—lung cancer	2.04e-07	1.96e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTEN—lung cancer	2e-07	1.92e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—lung cancer	1.99e-07	1.91e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CA—lung cancer	1.91e-07	1.84e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—EP300—lung cancer	1.91e-07	1.83e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTEN—lung cancer	1.88e-07	1.81e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTEN—lung cancer	1.87e-07	1.79e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CG—lung cancer	1.86e-07	1.79e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT1—lung cancer	1.84e-07	1.77e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—EP300—lung cancer	1.8e-07	1.72e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—EP300—lung cancer	1.78e-07	1.71e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—POMC—lung cancer	1.77e-07	1.7e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CREBBP—lung cancer	1.72e-07	1.66e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CD—lung cancer	1.63e-07	1.57e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CA—lung cancer	1.62e-07	1.55e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALB—lung cancer	1.61e-07	1.55e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AKT1—lung cancer	1.56e-07	1.5e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CB—lung cancer	1.42e-07	1.37e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—lung cancer	1.41e-07	1.36e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CA—lung cancer	1.41e-07	1.35e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CA—lung cancer	1.33e-07	1.28e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKT1—lung cancer	1.32e-07	1.27e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CA—lung cancer	1.32e-07	1.26e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTEN—lung cancer	1.23e-07	1.18e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—EP300—lung cancer	1.17e-07	1.13e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKT1—lung cancer	1.15e-07	1.11e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKT1—lung cancer	1.08e-07	1.04e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKT1—lung cancer	1.08e-07	1.03e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CA—lung cancer	8.68e-08	8.34e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKT1—lung cancer	7.09e-08	6.81e-07	CbGpPWpGaD
